L-NAME Hydrochloride: Benchmark NOS Inhibitor for Vascular Tone and Cardiovascular Research

Executive Summary: L-NAME Hydrochloride (NG-nitro-L-arginine methyl ester, A7088) is a competitive nitric oxide synthase inhibitor with an IC₅₀ of ~70 μM, extensively used to modulate NO production in cell and animal models (APExBIO). It induces dose-dependent increases in systemic arterial blood pressure and bradycardia, reversible by L-arginine, making it indispensable for vascular tone and cardiovascular disease research (Zhang et al., 2026). L-NAME specifically inhibits endothelial (eNOS), neuronal (nNOS), and inducible (iNOS) isoforms. In vitro, 1 mM L-NAME suppresses both nitric oxide and prostaglandin E2 production as well as iNOS and COX-2 expression in retinal cells under high glucose. The compound is highly soluble in water and DMSO but not ethanol, with recommended storage at -20°C for stability.

Biological Rationale

Nitric oxide (NO) is a key signaling molecule regulating vascular tone, neurotransmission, platelet aggregation, and immune responses (Zhang et al., 2026). NOS enzymes catalyze the oxidation of L-arginine to NO and L-citrulline. Dysregulation of NO synthesis is implicated in hypertension, endothelial dysfunction, atherosclerosis, and inflammation. Pharmacological inhibition of NOS allows researchers to dissect the role of NO in physiological and disease models, notably in cardiovascular research and studies of vascular smooth muscle function (see comparative review—this article expands on quantitative evidence and application limits).

Mechanism of Action of L-NAME Hydrochloride

L-NAME Hydrochloride acts as a competitive inhibitor of nitric oxide synthase. Structurally analogous to L-arginine, it binds to the NOS active site, outcompeting the substrate and thus inhibiting conversion to NO. This inhibition is reversible by excess L-arginine, a useful feature for mechanistic studies. L-NAME inhibits all three NOS isoforms: eNOS (endothelial), nNOS (neuronal), and iNOS (inducible), though potency may vary by isoform and experimental conditions (Zhang et al., 2026). The compound’s efficacy is dose-dependent, with in vitro IC₅₀ ~70 μM and full inhibition typically achieved at 0.5–1 mM in cellular systems. In vivo, intravenous doses of 0.03–300 mg/kg in rats yield robust, reversible increases in blood pressure and bradycardia, confirming systemic NOS inhibition (APExBIO).

Evidence & Benchmarks

• L-NAME Hydrochloride inhibits NOS activity in rat brain and porcine aortic endothelial preparations with dose-dependent efficacy (APExBIO).
• IC₅₀ for NOS inhibition is approximately 70 μM under standard in vitro assay conditions (pH 7.4, 37°C) (APExBIO).
• Intravenous L-NAME (0.1–10 mg/kg) in rats increases mean arterial blood pressure by 20–40 mmHg; these effects are reversed by L-arginine administration (Zhang et al., 2026).
• At 1 mM, L-NAME suppresses high-glucose-induced NO and prostaglandin E2 production, iNOS, and COX-2 expression in retinal cells, reducing apoptosis (Zhang et al., 2026).
• The compound is water-soluble (≥27 mg/mL), DMSO-soluble (≥23 mg/mL), and ethanol-insoluble; it is chemically stable at -20°C for short-term use (APExBIO).

This article updates prior summaries (see here) by integrating precise dose-response data and clarifying the context of non-endothelial applications.

Applications, Limits & Misconceptions

L-NAME Hydrochloride is extensively employed in:

• Vascular tone regulation studies and hypertension research (complementary review—this article clarifies dose dependency and reversibility by L-arginine).
• Modeling endothelial dysfunction in cardiovascular disease (see detailed protocols—this article emphasizes solubility and storage parameters for reproducibility).
• Dissecting the roles of NO in inflammation, apoptosis, and gene regulation.
• Investigating the PI3K/Akt/eNOS signaling pathway in vascular and cellular models.

Common Pitfalls or Misconceptions

• L-NAME does not selectively inhibit a single NOS isoform; it affects eNOS, nNOS, and iNOS to varying degrees.
• NO-independent pathways are not blocked: L-NAME does not affect non-NOS-mediated signaling or direct redox processes.
• Reversibility requires L-arginine supplementation: Without excess substrate, inhibition persists.
• Solubility constraints: L-NAME is insoluble in ethanol, limiting certain formulation options.
• Long-term solution storage is not recommended; use freshly prepared solutions for maximal activity.

Workflow Integration & Parameters

L-NAME Hydrochloride (A7088, APExBIO) is supplied as a solid, with a molecular weight of 269.7 g/mol and chemical formula C₇H₁₅N₅O₄·HCl. For in vitro use, dissolve in water (≥27 mg/mL) or DMSO (≥23 mg/mL). Avoid ethanol as a solvent. Store powder at -20°C; prepare solutions fresh before use to ensure stability (APExBIO).

Typical parameters:

• Cellular assays: 0.1–1 mM final concentration (incubation at 37°C, pH 7.4, 24–48 h).
• Animal models: 0.03–300 mg/kg intravenous dosing in rats (effects monitored via arterial pressure, heart rate).
• Controls: Include vehicle (solvent), L-arginine rescue, and baseline physiological measurements.

For advanced troubleshooting and protocols, see the expanded workflows in the Advanced Insights article; this current article details solubility, reversibility, and IC₅₀ data not previously emphasized.

Conclusion & Outlook

L-NAME Hydrochloride remains the benchmark NOS inhibitor for vascular, neurological, and inflammation research, offering precise, reproducible modulation of NO-dependent pathways. Its robust dose-response, reversibility by L-arginine, and established use in both in vitro and in vivo models underpin its value for dissecting NO signaling and modeling cardiovascular disease (Zhang et al., 2026). Researchers are advised to observe solvent and storage recommendations, employ appropriate controls, and interpret results with consideration of non-selective NOS inhibition. For further technical details and ordering, refer to APExBIO's L-NAME Hydrochloride product page.